TRPM4 targeting and proteasomal degradation of TRPM4 by Acetalax and bisacodyl. A, Western blot of TRPM4 protein levels in MDA-MB468 following Acetalax treatment. B, Western blot of TRPM4 protein levels in MDA-MB468 following Acetalax and MG132 proteasome inhibitor treatment. C, Western blot of TRPM4 protein levels in MDA-MB468 following bisacodyl treatment. D, Western blot of TRPM4 protein levels in MDA-MB468 following bisacodyl and MG132 proteasome inhibitor treatment. The presence or absence of Acetalax or bisacodyl and MG132 is indicated in each experiment by + and/or − above each column. Cells were treated with Acetalax for 4 hours at 10 μmol/L and bisacodyl at 30 μmol/L. Cells were treated with MG132 for 4 hours at 20 μmol/L.
No takes yet. Share an insight, caveat, or question.
Mizunuma et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: